• Metal chelation
• Cellular growth & differentiation
Supplement FactsServing Size:3 scoops
Modified Citrus Pectin … 15 g*
*Contains 885 mg of sodium and up to 1350 mg of potassium per day.
Non-medicinal ingredients: none.
Note: Herbal extracts will naturally vary in color and taste from one batch to another.
AOR Guarantees: that no ingredients not listed on the label have been added to the product. Contains no peanuts, eggs, fish, shellfish or any animal byproduct.
Source: Orange Peel
What Is It?
MCP is modified citrus pectin, a carbohydrate derived from the soluble fiber of citrus peels that has been broken down into smaller fragments to be more easily absorbed in the digestive tract and effective in the body.
What Does It Do?
Primary Uses: Pectins from citrus fruits contain high amounts of galactose, which can be used to provide an alternate binding site for abnormal cells instead of to galactose residues on healthy tissues, thereby reducing the spreading of abnormal cells. Animal studies have shown tremendous results in this area, while human studies have shown modest results, especially in prostate patients.
Secondary Uses: Heavy metal toxicity is known to be an important factor in declining general health. Adult case reports, one short study in healthy people and one small clinical study in young children have shown tremendous effectiveness for MCP in reducing heavy metal toxicity including lead, mercury, arsenic and cadmium. Larger clinical trials are required for greater conclusiveness, but results like heavy metal reductions by up to 560% are mind-blowing.
Who Should Take It?
MCP may provide support for those battling abnormal cellular growth, buying more time to allow conventional treatments to take effect. MCP is also a powerful chelator for those who require heavy metal detoxification.
Take 1 scoop mixed with water or juice 3 times daily with food or immediately after meals (to minimize gastrointestinal irritation and prevent too rapid absorption), or as directed by a qualified health care practitioner.
AzÉmar M, Hildenbrand B, Haering B, Heim ME, Unger C. Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study. Clinical Medicine: Oncology 2007:1, 73–80.
Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modified citrus pectin on urinary excretion of toxic elements. Phytotherapy Research, 2006; 20(10): 859–864.
Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modified citrus pectin/alginates in heavy metal chelation and detoxification–five case reports. Forsch Komplementmed. 2007 Dec;14(6):358-64.
Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.
Hsieh TC, Wu JM. “
Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin.”
Biochem Mol Biol Int. 1995 Nov; 37(5): 833-41.
Inohara H, Raz A. “
Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions.”
Glycoconj J. 1994 Dec; 11(6): 527-32.
Liu Y, Ahmad H, Luo Y, Gardiner DT, Gunasekera RS, McKeehan WL, Patil BS. “
Citrus pectin: characterization and inhibitory effect on fibroblast growth factor-receptor interaction.”
J Agric Food Chem. 2001 Jun; 49(6): 3051-7.
Naik H, Pilat MJ, Donat T. “
Inhibition of in vitro tumor cell-endothelial adhesion by modified citrus pectin: a pH modified natural complex carbohydrate.”
Proc Am Assoc Cancer Res. 1995; 36: A377.
Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. “
Galectin-3 induces endothelial cell morphogenesis and angiogenesis.”
Am J Pathol. 2000 Mar; 156(3): 899-909.
Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A. “
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.”
J Natl Cancer Inst. 1995 Mar 1; 87(5): 348-53.
Platt D, Raz A. “
Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin.”
J Natl Cancer Inst. 1992 Mar 18; 84(6): 438-42.
Zhao ZY, Liang L, Fan X, Yu Z, Hotchkiss AT, Wilk BJ, Eliaz I. The role of modified citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 Jul-Aug;14(4):34-8.
Canada and USA
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.